Patents by Inventor Paul J. Balderes

Paul J. Balderes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment
    Patent number: 9375488
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 28, 2016
    Assignees: ImClone, LLC, ImmunoGen, Inc.
    Inventors: Paul J. Balderes, Scott W. Eastman, Hans K. Erickson, Dale L. Ludwig, Christopher M. Moxham, Gregory D. Plowman, Alan C. Rigby
  • COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND METHODS OF TREATMENT
    Publication number: 20150165067
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 18, 2015
    Applicants: IMCLONE LLC, IMMUNOGEN, INC.
    Inventors: Paul J. BALDERES, Scott W. EASTMAN, Hans K. ERICKSON, Dale L. LUDWIG, Christopher M. MOXHAM, Gregory D. PLOWMAN, Alan C. RIGBY
  • Anti-TYRP1 antibodies
    Patent number: 7951370
    Abstract: The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: May 31, 2011
    Assignee: ImClone LLC
    Inventors: Paul J. Balderes, Xiaoqiang Kang
  • ANTI-TYRP1 ANTIBODIES
    Publication number: 20090232823
    Abstract: The present invention provides for fully human antibodies and chimeric antibodies that bind human TYRP1 antigen with an affinity comparable to or higher than TA99, a murine antibody specific to TYRP1. The invention further provides polynucleic acids and host cells that encode and express these antibodies. The invention also provides for methods of modulating activity of TYRP1, treating growth of a cancer cell, and treating a malignant melanoma in mammals by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment.
    Type: Application
    Filed: March 11, 2009
    Publication date: September 17, 2009
    Inventors: Paul J. Balderes, Xiaoqiang Kang